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Abstract
D-cycloserine is an effective second line antibiotic used as a last resort to treat multi (MDR)- and
extensively (XDR)- drug resistant strains of Mycobacterium tuberculosis. D-cycloserine interferes
with the formation of peptidoglycan biosynthesis by competitive inhibition of Alanine racemase
(Alr) and D-Alanine-D-alanine ligase (Ddl). Although, the two enzymes are known to be
inhibited, the in vivo lethal target is still unknown. Our NMR metabolomics work has revealed that
Ddl is the primary target of DCS, as cell growth is inhibited when the production of D-alanyl-D-
alanine is halted. It is shown that inhibition of Alr may contribute indirectly by lowering the levels
of D-alanine thus allowing DCS to outcompete D-alanine for Ddl binding. The NMR data also
supports the possibility of a transamination reaction to produce D-alanine from pyruvate and
glutamate, thereby bypassing Alr inhibition. Furthermore, the inhibition of peptidoglycan
synthesis results in a cascading effect on cellular metabolism as there is a shift toward the
catabolic routes to compensate for accumulation of peptidoglycan precursors.
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INTRODUCTION
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality from a
single infectious disease on a global perspective.1 In 2011, 8.7 million people were infected
with TB with over 1.8 million deaths world-wide. Moreover, the emergence of multiple-
(MDR-TB) and extensively drug-resistant- (XDR-TB) Mycobacterium tuberculosis strains
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threaten to curtail efforts in disease control. Currently, about 3.7% of new TB patients are
infected with MDR-TB. A better understanding of the molecular mechanisms of action and
resistance to existing antibiotics, and the development of novel drugs that are more potent
and safer is urgently needed.
D-cycloserine (DCS) is a second line drug that is currently used as a last resort on MDR-and
XDR-TB. DCS has been used to treat TB for over fifty years despite a lack of knowledge
regarding the identity of its lethal target.2 Although DCS inhibits bacterial cell growth, it has
serious neurological side effects.3–5 DCS treatment results in psychosis, depression, and
convulsions, among other issues. In this context, DCS has also been tested in neurological
studies and has been shown to act as a partial agonist of N-methyl-D-aspartate (NMDA) and
glycine receptors.6 Thus, understanding the source of DCS antimicrobial activity would
enable the development of next-generation antibiotics for TB that avoids these CNS side
effects. DCS is a cyclic analogue of D-alanine and has been shown to competitively inhibit
Alanine racemase (Alr, EC 5.1.1.1) and D-alanine-D-alanine ligase (Ddl, EC 6.3.2.4).7, 8
Correspondingly, the current understanding of DCS activity against mycobacteria is through
the inhibition of Alr and/or Ddl that halts the synthesis of peptidoglycan precursors.
However, we previously demonstrated that Alr is not the lethal target of DCS, suggesting
Ddl is the primary target in live mycobacteria.9 Moreover, we have now isolated new alr
null mutants of M. smegmatis and M. tuberculosis that are not dependent for D-alanine
under appropriate growth conditions, indicating that alr is not an essential gene in
mycobacteria (unpublished results). This is also consistent with the observation by
Takayama et al. that the UDP-MurNAc-tripeptide accumulates in M. tuberculosis upon
treatment with DCS.10 UDP-MurNAc-tripeptide is the product of the meso-
diaminopimelate- adding enzyme (EC 6.3.2.13) in the peptidoglycan biosynthesis pathway,
while the next step involves the MurF D-alanyl-D-alanine adding enzyme (EC 6.3.2.10)
ligating the UDP-MurNAc-tripeptide with D-alanyl-D-alanine, the product of Ddl.11
Clearly, the inhibition of Ddl by DCS would decrease the production of D-alanyl-D-alanine
and lead to the observed accumulation of the UDP-MurNAc-tripeptide, as the co-substrate
of the MurF reaction is decreased.
Peptidoglycan biosynthesis is an ideal target for drug design because the pathway is not
present in mammalian cells.11 Also, the resulting peptidoglycan-arabinogalactan complex
gives the cell its structural integrity.11–13 The peptidoglycan layer consists of an alternating
N-acetylglucosamine and N-glycolated or N-acetylated muramic acid. Each N-glycolated or
N-acetylated muramic acid is bound to a tetrapeptide consisting of an L-alanyl–D-
isoglutaminyl–meso-diaminopimelyl–D-alanine (L-Ala–D-Glu–A2pm–D-Ala) moiety. The
tetrapeptide forms a crosslink between adjacent alternating aminosugars where the side
chain of meso-diaminopimelate of one group forms a peptide bond with a D-alanine residue
from the adjacent group. This large mycolyl-arabinogalactan-peptidoglycan complex creates
an impermeable barrier that is essential for the viability of the cell.14 This metabolic route
includes the D-alanine branch pathway consisting of three enzymes that contribute to the
synthesis of the glycomuramyl pentapeptide involved in the crosslinking of mature
peptidoglycan. Alr is a pyridoxal phosphate dependent enzyme that interconverts L-alanine
and D-alanine.15, 16 The ATP Ddl catalyzes the subsequent peptide bond between two D-
alanine moieties.17 The final step is the addition of this dipeptide to the glycomuramyl
tripeptide cytoplasmic precursor by the ATP-dependent MurF adding enzyme to form the
pentapeptide complex.18 As a result, numerous enzymes within the peptidoglycan
biosynthesis machinery recognize or bind a D-alanine moiety and are potentially inhibited
by DCS. Herein, we describe our application of Nuclear Magnetic Resonance (NMR) based
metabolomics and bioinformatics to determine the lethal target of DCS in mycobacteria and
to investigate the effects of this drug on central metabolic pathways related to peptidoglycan
biosynthesis. Our analysis indicates that DCS is a promiscuous inhibitor targeting multiple
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enzymes within the peptidoglycan biosynthesis pathway, but Ddl is the primary target. Our
results also support the prior observation by Caceres et al.19 that D-alanine is a competitive
inhibitor of DCS and its over-production is a primary mechanism of resistance.
METHOD AND MATERIALS
Preparation of M. tuberculosis NMR Metabolomics Samples
General procedures for the handling and preparation of M. tuberculosis NMR samples for
metabolomic analysis have been described elsewhere.20 Six (3 for 13C-D-alanine and 3
for 13C-D-alanine DCS) M. tuberculosis H37Rv 110 mL MADC broth (Middlebrook 7H9
complete media) cultures from glycerol stock were grown shaking at 100 rpm at 37°C for
approximately 7 days (OD600 0.6–0.8). A 500 μl sample was removed and kept at 4°C for
colony-forming unit (CFU) determinations. 13C-D-alanine (0.1 mM final concentration; e.g.
100 μl of a 100 mM stock) was added to all cultures. DCS (50 μg/mL final concentration
(500 μl of a 10 mg/mL stock)) was added to only 3 flasks. All cultures were incubated for an
additional 18 hours, taking another OD600 reading and removing a 500 μl sample from each
flask. Cultures were placed on ice for 5 minutes and left on ice throughout the rest of the
processing. Cultures were harvested by spinning them down at 2000 g at 4°C for 15 minutes
in 50 mL tubes. The samples were washed two times (~25–30 mL) with ice-cold double
distilled water (ddH2O). The cell pellets were resuspended with 1 mL of ddH2O and
transferred to a 2 mL vial consisting of 0.1 mm silica beads (Lysing Matrix B). The cells
were then lysed using a FastPrep-24 instrument for 60 seconds at 6 m/s. The cellular mixture
was centrifuged at 15,000 g at 4°C for 10 minutes and the supernatant was extracted to a 1.5
mL tube. 700 μl of ddH2O was added to the tube containing the lysing matrix B and briefly
vortexed, followed by centrifugation, and then transferring and combining the supernatants
in a 1.5 mL tube. The supernatant was syringe filtered (0.2 Mm) into a sterile tube. A 100
Ml of the sample (10%) was plated on MADC to verify that there are no live cells. Samples
were frozen in an EtOH-dry ice bath and stored at −80°C for 2 months. After verification
that the plates contained no viable cells (CFUs), the metabolomic samples were taken out of
BSL3 containment, lyophilized and prepared for analysis by NMR. 10 μL of the supernatant
was used to determine protein concentration as described below for the M. smegmatis
samples.
Preparation of M. smegmatis NMR Metabolomics Samples
NMR samples for 2D 1H-13C HSQC experiments were prepared from 6 groups of triplicate
and independent M. smegmatis mc2155 cultures using 100 μM 13C2-D-alanine (13Cα
and 13Cβ labeled) or 13C3-pyruvate as a carbon-13 source. The following groups using 13C2-
D-alanine are mc2155 as a control and mc2155 treated with 75, 300, or 1200 μg/mL of DCS.
The groups using 13C3-pyruvate are untreated mc2155 and mc2155 treated with 75 μg/mL
DCS. The replicate cultures were grown at 37°C with shaking at 200 rpm in 110 mL of
MADC (250 mL flask) until an OD600 of 0.6 was met. 13C2-D-alanine or 13C3-pyruvate was
inoculated to the designated cultures for a final concentration of 100 μM. The cultures were
allowed to grow for 10 minutes and then were treated with DCS to a final concentration of
75, 300, or 1200 μg/mL. The cultures were then grown for an additional 2 hours before
harvesting. Each culture was placed on ice for 5 minutes and then centrifuged for 10 minutes
at 1500 g and 4°C. The cell pellets were washed twice with 30 mL of ice-cold ddH2O. The
cell pellets were re-suspended with 1 mL of ddH2O and transferred to a 2 mL vial consisting
of 0.1 mm silica beads. The cells were then lysed using a FastPrep-24 instrument for 40
seconds at 6 m/s. The cellular mixture was centrifuged for 10 minutes at 12,400 g and 4°C
and the supernatant was extracted. 10 μL of the supernatant was used to determine the
protein concentration in the extracted metabolomics sample. Bio-Rad DC Protein Assay was
used to obtain the total protein concentration for each sample using bovine serum albumin as
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a standard. The supernatant was frozen in a dry ice ethanol bath and stored at −80°C until
analyzed by NMR.
Two groups of triplicate and independent M. smegmatis mc2155 cultures were also grown
using 13C6-glucose as the carbon-13 source. The two groups are untreated mc2155 and
mc2155 treated with 75 μg/mL DCS. The cell cultures were grown in 50 mL of minimal
media containing 22 mM 13C6-glucose, 500 mM ammonium chloride, and essential salts.
The pH of the minimal media was adjusted to 7.2. The cultures were grown as described
above until an OD600 of 0.6 was achieved. DCS was then added to the selected cultures to a
concentration of 75 μg/mL and the bacteria were allowed to grow for 2 more hours. The
metabolome was extracted as described above.
Prior to collecting the 2D 1H-13C HSQC spectra, all metabolomics samples are lyophilized
and re-suspended in a 500 mM potassium phosphate buffer in 99.8% D2O at a pH of 7.2
(uncorrected) containing 500 μM of unlabeled 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid
sodium salt (TMSP) as an internal standard. The volume used for each sample was
normalized based on the relative protein concentration determined for each sample. The
sample with the lowest protein concentration was dissolved in 650 μL of the NMR buffer,
where the other samples were dissolved in a proportionally larger buffer volume based on
the relative protein concentrations. In this manner, the final metabolomics sample
concentrations were equivalent and directly comparable. 600 μL of the reconstituted
metabolomics sample was then placed into a 5 mm NMR tube for data collection.
2D 1H-13C HSQC NMR Data Collection
The 2D 1H-13C HSQC NMR spectra were collected on a Bruker 500 MHz Avance DRX
spectrometer equipped with a triple-resonance, Z-axis gradient cryoprobe. A BACS-120
sample changer with Bruker Icon software was used to automate the NMR data collection.
All spectra were collected using the Time-Zero HSQC (HSQC0) pulse sequence and
followed the experimental protocol as previously described.21 Briefly, the relative intensity
of a peak in a standard 2D 1H-13C HSQC NMR spectrum is dependent on the metabolite
concentration and a number of other factors, such as the magnitude of the J-coupling
constant, relaxation processes and dynamics. Instead, the HSQC0 experiment collects a
series of three HSQC experiments with an increasing number of pulse sequence repetitions
(HSQC1, HSQC2, HSQC3). Correspondingly, the peak intensity will decrease proportionally
with the number of pulse sequence repetitions due to the impact of J-coupling, relaxation,
and other factors. Thus, the peak intensity can then be plotted as a function of the number of
pulse sequence repetitions and extrapolated back to time-zero (HSQC0). The peak intensity
at time-zero is only dependent on metabolite concentration. The 2D 1H-13C HSQC NMR
spectra were collected for 2 hours each with a total of 2048 data points and a spectrum width
of 5000.0 Hz, and 64 data points with a spectrum width of 17607.23 Hz in the 1H and 13C
dimensions, respectively. A total of 16 dummy scans, 128 scans, a receiver gain of 9195.2,
and a relaxation delay of 1.5 seconds was used to obtain all spectra. A total of 109
2D 1H-13C HSQC NMR spectra were collected requiring approximately 218 hours of NMR
spectrometer time to analyze the impact of DCS on M. tuberculosis and M. smegmatis.
2D 1H-13C HSQC NMR Data Analysis
All 2D NMR spectra were processed using the NMRpipe software package.22 A reference
spectrum for peak picking was created by adding all spectra together. All spectra including
the reference spectra was automatically peak picked and the peak intensities were organized
by their chemical shifts using NMRviewJ.23 The observed NMR peaks were assigned to
specific metabolites using 1H and 13C chemical shift tolerances of 0.05 and 0.40 ppm
respectively. Metabominer,24 Madison Metabolomics Consortium Database (MMCD),25
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Human Metabolome Database (HMDB),26 and Platform for Riken Metabolomics
(PRIME)27, 28 were used to identify all metabolites. All identified metabolites were verified
using KEGG29 and MetaCyc30 databases.
The concentrations of all metabolites were calculated using an extrapolation procedure that
has been previously described.21 The concentration for each metabolite from the triplicate
datasets are then averaged, standard deviation was calculated, and Student’s t-tests were
used to test for statistical significant (p < 0.05) differences between each group.
NMR Ligand Binding Assay for D-Alanine-D-alanine Ligase
M. tuberculosis D-Alanine-D-alanine ligase was obtained using protocols described
previously.17 Ligand binding assays were performed to determine if alanine, ATP, and DCS
can bind to the ligase individually or in combination. Six combinations of each ligand were
used: 1) ATP, 2) D-alanine 3) DCS, 4) ATP and D-alanine 5) ATP and DCS, and 6) ATP,
D-alanine, and DCS. The final concentration for each ligand is 100 μM. A second set of the
six combinations of ligands were prepared identically, but with the addition of 25 μM of D-
Alanine-D-alanine ligase. NMR inhibition studies of the D-Alanine-D-alanine ligase were
performed using multiple concentrations of D-alanine and DCS. A total of 4 mixtures were
prepared using 100 μM D-alanine with 0, 250, 500, or 1000 μM DCS. ATP was kept at a
high concentration of 6 mM to prevent any competitive inhibition by low ATP:ADP ratios.
D-Alanine-D-alanine ligase was titrated into the solution for a final concentration of 25 μM.
Each of the NMR samples was dissolved in 600 μL of 50 mM Tris buffer (pH 8.0,
uncorrected) consisting of 10 mM magnesium chloride, 11.1 μM TMSP, and 2% DMSO.
1D 1H NMR spectra were collected using excitation sculpting to efficiently remove the
solvent signal.31 A total of 16k data points with a spectrum width of 5482.5 Hz were
collected using 32 scans and 8 dummy scans. The acquisition time for each 1D 1H NMR
spectrum was approximately 5 minutes. A total of 34 1D 1H NMR spectra were collected
requiring approximately 170 minutes of NMR instrument time. The 1D 1H NMR spectra
were processed using ACD 1D NMR manager version 12.0. The peak area for D-alanine
and D-alanyl-D-alanine was determined and the concentration was calculated based on the
TMSP peak.
RESULTS
Overall Impact of DCS on Mycobacterium smegmatis and Mycobacterium tuberculosis
Metabolomes
In our previous studies, we found that M. smegmatis alr null mutants were able to grow on
Middlebrook 7H9 medium without D-alanine supplementation.32, 33 Furthermore, principal
component analysis (PCA) of NMR metabolomics data revealed that M. smegmatis alr null
mutants had different clustering patterns in PCA scores plots than the wild type and resistant
strains indicating that Alr inactivation had a major impact on the metabolome.9 However,
the wild type and alr mutant cells treated with DCS cluster together in the PCA scores plot,
but separate from untreated alr mutant cells, indicating that DCS acts on a common target
different from Alr. Also, the one-dimensional (1D) 1H NMR metabolomics data showed that
glutamate and pyruvate may be a source for D-alanine synthesis, suggesting that a
transaminase may convert D-(L-)glutamate and pyruvate into D-alanine and α-ketoglutarate
(Fig. 5). The heterologous racemization of amino acids by a bacterial transaminase has been
previously observed.34 Thus, Alr is not an essential function of mycobacteria and is not the
lethal target of DCS. We hypothesized that the inhibition of a secondary target, possibly
Ddl, may negatively impact cell survival and function as the lethal target.
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To analyze in depth the mechanism of action of DCS in both M. smegmatis and M.
tuberculosis, a comparison of the impact of DCS on both microorganisms was performed
using NMR metabolomics (Fig. 1).Typically, metabolites from cell extracts are detectable
by 1H-NMR where the intensities of each peak correlate with the concentrations of the
metabolites. Therefore, any differences in peak intensity between organisms indicate a
difference in the metabolomes. A spectral comparison between these two species indicates
that there are few differences in the metabolomes (Fig. 1a). More noticeable, the M.
tuberculosis metabolome shows a higher concentration of carbohydrates and aminosugars
(3.5–4.5 ppm). However, the impact of DCS is similar for both M. smegmatis and M.
tuberculosis suggesting the mechanism of DCS inhibition is similar in both species. The
1D 1H-NMR spectrum indicates that alanine (1.43–1.45 ppm) showed a large increase while
glutamate (2.00–2.45 ppm) had a dramatic decrease in concentration when both M.
smegmatis and M. tuberculosis were treated with DCS (highlighted by blue boxes). In M.
tuberculosis, there is an increase in the concentration of UDP, acetate, α-ketoglutarate while
there is a decrease in AMP, glutamine, and methionine (Fig. 1b). An increase in UDP would
be expected because it is an important precursor for peptidoglycan synthesis by providing N-
acetyl(glycolyl)-glucosamine and the corresponding muramate UDP-derivatives.
To further quantify metabolite changes resulting from DCS treatment, we collected
2D 1H-13C HSQC spectra after supplementing the bacterial growth medium with a
carbon-13 source. This procedure allows for monitoring the carbon-13 flow through the
metabolome. Since the natural abundance of carbon-13 is 1.1%, only compounds derived
from the 13C-labeled metabolite through enzymatic turnover will be detected in the
2D 1H-13C HSQC spectrum. As the D-alanine pathway is the primary focus of our study,
both M. smegmatis and M. tuberculosis cells were pulse labeled with 13C-D-alanine and
treated with DCS shortly thereafter. Cells were further grown for approximately half to one
generation and harvested. Not surprisingly, the resulting 2D 1H-13C HSQC spectrum of the
metabolomes obtained from the two untreated mycobacterial species cells differed (Fig. 1
c,d). As observed in the 1D spectra, the M. tuberculosis peaks in the 2D 1H-13C HSQC
spectrum appear to be more congested in the carbohydrate and aminosugar region (13C =
60–80 ppm, 1H = 3.0–4.5 ppm). Therefore, the carbon-13 flow for M. tuberculosis appears
to be directed towards gluconeogenesis. This differs from M. smegmatis, where the peaks
are well dispersed throughout the 2D 1H-13C HSQC spectrum and correspondingly in the
metabolome.
Again, the impact of DCS appears to be similar for both M. smegmatis and M. tuberculosis
as three additional peaks clearly appeared in both 2D 1H-13C HSQC spectra upon drug
treatment (circled region in Fig. 1c,d). Using metabolomics databases containing reference
NMR spectra, we were able to identify one of the peaks as alanine (13Cα 56.0 ppm, 1Hα
3.54 ppm). This is consistent with the inhibitory effect of DCS on Ddl that may lead to an
accumulation of 13C-D-alanine. However, the two nearby peaks were not identified from the
NMR databases. Based on the peak intensities and chemical shifts, it was suspected to be a
close derivative of D-alanine. To test this hypothesis, we collected the natural abundance
spectrum of a solution of D-alanyl-D-alanine as a reference. The two unknown peaks were a
perfect match to this D-alanyl-D-alanine reference spectrum (Fig. 1e) indicating that D-
alanyl-D-alanine is accumulated upon DCS treatment with supplemental 13C-D-alanine.
This result was expected from Alr inhibition by DCS and the flow of the 13C label into D-
alanyl-D-alanine35 as Ddl activity is maintained because the supplemented 13C-D-alanine
effectively competes with DCS for the Ddl active site.19 Further inspection of cell growth
curves confirmed that the DCS treated cultures when supplemented with 13C-D-alanine
were growing similarly to untreated cells. Thus, 13C-D-alanine appears to compete very
effectively with DCS and promote cell viability in the presence of DCS. This effect would
readily explain the well-known reversal of DCS inhibition by D-alanine.36
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Impact of DCS on the Central Metabolism and Peptidoglycan Synthesis
To study the impact of DCS on M. smegmatis, a detailed analysis of changes to the
metabolome was performed by measuring the 13C metabolite concentrations using 2D time-
zero 1H-13C HSQC (HSQC0) experiments.21 Two sets of triplicate cultures were grown in
minimal media with 13C-glucose as the primary carbon source. Cells were grown to
exponential phase, treated with 75 μg/mL of DCS and grown for one additional generation.
Analysis of the corresponding cell extracts (Fig. 2a) indicated that the variations in the
metabolites identified from the HSQC0 experiment were similar to those identified from the
1D 1H-NMR spectra (Fig. 1a,b). This further confirms that carbohydrate precursors leading
towards the biosynthesis of trehalose, glycogen, rhamose and UDP-galactose were
significantly decreased upon DCS treatment. Moreover, the increase in fructose-1,6-
bisphosphate highlights the switch to the catabolic route suggesting up-regulation of the
glycolytic pathway. Glutamate is an important metabolite for energy generation, purine
synthesis, peptidoglycan synthesis, and transfer of amino groups. Consistent with these
roles, glutamate was greatly decreased in the presence of DCS suggesting the metabolite
was catabolized. This same catabolic effect was observed on the pools of nucleotide
precursors such as dUMP, dCMP, dTDP, and thymidine, which were all decreased
significantly upon DCS treatment. There is also a significant decrease in the concentration
of precursors in the oxidative branch of the pentose phosphate pathway such as D-glucono-
1,5-lactone and 6-phosphogluconate. But, there is also an increase in the concentration of D-
ribose-5-phosphate and D-ribose, suggesting a switch to the non-oxidative branch of the
pentose phosphate pathway.
β-alanine is the precursor of important vitamins such as panthotenate via the conversion of
aspartate to β-alanine by the PanD enzyme. Moreover, pantothenate is a precursor of
Coenzyme A, which is essential for the production of fatty acids and peptidoglycan. A
significant decrease in the pool of β-alanine was also observed, potentially suggesting DCS
may inhibit the PanD enzyme. Instead, the fluxes of carbon precursors is rerouted towards
the production of methionine and lysine, the terminal product of the pantothenate pathway
immediately downstream from meso-2-6-diaminopimelate, a component of the
peptidoglycan bridge. However, the increase in concentration of N-alpha-acetyl-lysine
suggests that lysine is also being catabolized. Other peptidoglycan precursors such as
alanine, UDP-N-acetyl-glucosamine, UDP, D-ribose, D-ribose-5-phosphate, and carbamoyl-
L-aspartate are all significantly increased, consistent with the inhibition of peptidoglycan
biosynthesis.
These results were confirmed by a second metabolomics study using 13C-pyruvate as a
carbon-13 source (Fig. 2b). Carbon flow was initially directed toward gluconeogenesis and
glutamate production. However, trehalose, myoinositol, glucose-1-phosphate and glutamate
decreased significantly upon DCS treatment. Consistent with the inhibition of peptidoglycan
synthesis, the fluxes of carbon precursors was also directed towards purine and lysine
biosynthesis, as observed by the significant increase in UDP, N-carbamoyl-L-aspartate, and
N-alpha-acetyl-lysine. There was also a significant increase in proline concentration as the
metabolism of this amino acid plays an important role in the detoxification of
methylglyoxal, a toxic aldehyde generated from the cleavage of the phosphate group of
dihydroxyacetone phosphate by the enzyme methylglyoxal synthase.37 The over production
of methylglyoxal has been associated with the imbalance in the anabolic and catabolic
processes in the cell.38 Although we were unable to identify methylglyoxal, the increase in
proline levels suggests the existence of a mechanism to compensate for excessive activity in
the catabolic pathways.
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Effect of D-alanine on DCS Inhibitory Activity
To determine the effect of DCS on the D-alanine pathway, M. smegmatis cultures were
grown in Middlebrook 7H9 media supplemented with 100 μM 13C-D-alanine at mid-
exponential phase. After 10 min incubation, cultures were treated with either 75, 300, or
1200 μg/mL of DCS. To determine the uptake of 13C-D-alanine, the total area under the
peaks observed in the 2D 1H-13C HSQC spectra was compared between treated and
untreated samples. This is possible because all of the peaks in the 2D 1H-13C HSQC
spectrum are derived from 13C-D-alanine. We observed that D-alanine was able to
effectively compete with DCS for uptake. At 75 and 300 μg/mL the total carbon-13
concentration was approximately 35% higher in the DCS-treated cultures. This indicated
that D-alanine uptake was increased as needed to produce peptidoglycan precursors and
increase the internal D-alanine pools to out-compete DCS from internal targets such as Alr
and Ddl. However, a 15% decrease in D-alanine uptake was observed at 1200 μg/mL DCS,
which represents a 100-fold molar excess of DCS.
D-alanine readily reversed cell growth inhibition by DCS. For example, cell growth was
inhibited when cultures were grown with 13C-pyruvate and 13C-glucose using 75 μg/mL
DCS. Upon addition of 100 μM 13C-D-alanine to the culture medium, growth inhibition was
not observed even with 300 μg/mL DCS. Consistent cell growth inhibition only occurred
when the DCS dosage was raised to 1200 μg/mL, a 100-fold molar excess of DCS to D-
alanine (Fig. 3a). Comparison between non-inhibitory and inhibitory conditions was
important to assess the transient effect of DCS on the metabolome (Fig. 3b). At 75 or 300
μg/mL DCS, the overall impact on the metabolome was minimal, as indicated by the
corresponding heat maps of metabolite concentrations derived from 13C-D-alanine (Fig. 3a).
However, major changes were observed in cultures treated with 1200 μg/mL DCS, a
concentration resulting in inhibition of both D-alanine uptake and cell growth.
Increasing the DCS concentration had a major impact on the pool of 13C-labeled metabolites
originating from 13C-D-alanine (Fig. 4). At 75 μg/mL DCS, the internal pool of D-alanine
increased 12-fold with respect to untreated culture. Similarly, a 4-fold increase in D-alanyl-
D-alanine and a slight increase (10%) in glutamate were also observed. At 300 μg/mL DCS,
the D-alanine concentration increased 4-fold compared to untreated cultures, while the D-
alanyl-D-alanine and glutamate concentrations increased further by 5.5-fold and 50%,
respectively. At 1200 μg/mL, both the D-alanine and D-alanyl-D-alanine concentrations
were similar in both treated and untreated cultures, while the glutamate concentration
decreased by 50%. Treatment with increasing DCS concentrations also leads to similar
changes in other metabolite pools. For example, an increase in DCS concentration results in
an increase in peptidoglycan precursors such as lysine and UDP. These results are consistent
with the hypothesis that D-alanine can be metabolized by three pathways: i) direct
stereospecific conversion into L-alanine by Alr, ii) dimerization into the peptidoglycan
precursor D-alanyl-D-alanine by Ddl, and iii) transamination into pyruvate with concomitant
formation of glutamate from α-ketoglutarate (Fig. 5). As pyruvate turnover is extremely fast
(Fig. 2b), the rapid incorporation of the 13C-label into glutamate may proceed in three steps:
i) conversion of D-alanine into pyruvate, ii) pyruvate turnover into α-ketoglutarate, and
finally iii) the incorporation of the 13C-label into glutamate by iteration of the first step as
required by the principle of microscopic reversibility. Thus, in absence of DCS, D-alanine is
rapidly converted into L-alanine by Alr as well as other metabolites such as D-alanyl-D-
alanine and glutamate. As the concentration of DCS is increased, Alr inhibition leads to
label accumulation in the alanine pool, while the D-alanyl-D-alanine pool remains constant
only decreasing at the higher DCS concentrations (1200 μg/mL) reflecting the inhibition of
Ddl. Moreover, though the conversion of D-alanine into L-alanine is inhibited, the results
indicate that part of this label is still converted into glutamate. These results suggest that
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DCS first inhibits Alr, but cell growth inhibition parallels the inhibitory effect of DCS on
Ddl. Moreover, there is a conversion of 13C-D-alanine into 13C-glutamate at all DCS
concentrations, suggesting that a DCS-insensitive transaminase converts 13C-D-alanine and
α-ketoglutarate into 13C-glutamate and 13C-pyruvate (as shown in Fig. 5). By the principle
of microscopic reversibility, this enzyme may also convert glutamate and pyruvate into D-
alanine and α-ketoglutarate. Nonetheless, the major conversion of alanine and α-
ketoglutarate into glutamate and pyruvate depends on a transaminase that uses L-alanine as a
substrate (e.g., EC 2.6.1.2), as the 13C-label incorporated into glutamate decreases
significantly upon Alr inhibition. Therefore, Ddl rather than Alr, is the main lethal target of
DCS, while a transaminase that uses (D-(L-) glutamate as substrates is responsible for the
alternative pathway of D-alanine biosynthesis (Fig. 5). It is important to note that other
enzymatic reactions that produce D-alanine are possible alternative explanations, such as the
Strickland reaction in the ornithine fermentation pathway39 or the decarboxylation of D-
(L-)-aspartate by a broad range D-amino acid transaminase (EC 2.6.1.21).40
Correspondingly, the observed PanD inhibition and decrease in β-alanine caused by DCS
may result from an increase in the production of CoA for the Strickland reaction. Of course,
the ornithine fermentation pathway that is composed of nine enzymes has not been identified
in mycobacteria. Alternatively, the observed increase in aspartate upon DCS treatment may
suggest D-aspartate is being converted into D-alanine through the activity of a D-amino acid
transaminase that uses D-(L-)-aspartate as substrates for decarboxylation. Nevertheless, this
still requires invoking the activity of a transaminase to explain the production of D-alanine
when Alr is inhibited by DCS.
There are many classes of transaminases that have been identified in bacteria, such as:
Aspartate transaminase (EC 2.6.1.1), Alanine transaminase (EC 2.6.1.2), 4-
Aminobutyrate-2-oxoglutarate transaminase (EC 2.6.1.19), D-amino acid (broad-range)/D-
Alanine transaminase (EC 2.6.1.21), and the branched-chain-amino acid transaminase (EC
2.6.1.42). Candidate genes for all of these enzymes, except D-amino acid transaminase, have
been identified in M. smegmatis and M. tuberculosis (Table 1). There are 26 additional
aminotransferases in the M. tuberculosis genome, with 8 being described as “probable
aminotransferase” without an assigned function.
Canonical D-Alanine transaminases have been found in Gram-negative proteobacteria
(Brucella, Legionella, Rhodobacter), and Gram-positive firmicutes (Bacillus, Enterococcus,
Lactobacillus, Listeria, Staphylococcus) based on information from the NCBI Protein
Database.41, 42 However, mycobacteria are weakly Gram-positive and have high GC
genome contents which is quite different from the major group of Gram-positive
microorganisms in the phylogenetic tree. Thus, it is not surprising that a homologous D-
alanine transaminase has not been identified in mycobacterial genomes. But using this lack
of homology to conclude that D-alanine transaminase is not present in mycobacteria is
premature.43 Aminotransferases are well-known to have relaxed substrate specificity and as
a result are increasingly used in the biosynthesis of challenging pharmaceuticals.44–46 Thus,
the mycobacterial genomes may still encode a non-homologous protein that can perform this
transamination reaction. In effect, the biochemical property of each aminotransferase needs
to be thoroughly assessed before a specific enzymatic activity can be excluded. For instance,
a D-amino acid transaminase has been identified in Listeria monocytogenes that provides an
alternative route of D-alanine biosynthesis.47 A Delta-Blast48 search using the L.
monocytogenes D-amino acid transaminase sequence identified two homologous proteins in
M. smegmatis and M. tuberculosis. While these proteins have been assigned to other
functions, it is still plausible that one of these proteins is involved in a transamination
reaction yielding D-alanine. Similarly, any of the probable aminotransferases present in the
M. tuberculosis genome may also be a D-amino acid transaminase.
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Impact of DCS on D-Alanine-D-alanine Ligase
To further investigate the interaction of DCS and the Ddl lethal target, the binding of
relevant potential ligands with Ddl were followed by NMR. Moreover, the influence of a
given ligand on the simultaneous or consecutive binding of another ligand was followed as
well. Previous studies have yielded dissimilar results regarding the dependency of D-alanine
binding on the presence of ATP in solution.8, 17 However, Prosser et al. used a D-alanine
ligase recombinant protein containing the intact polyhistidine tag that could have introduced
undesirable interactions. To resolve this issue, purified untagged Ddl was incubated with
ATP, D-alanine, or both ATP and D-alanine and binding was analyzed by NMR (Figs. 1S–
3S). The observed NMR peak broadening for ATP upon the addition of Ddl indicates that
ATP binds strongly to Ddl in the absence of D-alanine. Conversely, the D-alanine NMR
peaked is unaffected by the addition of Ddl in the absence of ATP, indicating that D-alanine
cannot bind to Ddl without ATP. The addition of ATP induces the binding of D-alanine to
Ddl and the conversion of D-alanine to D-alanyl-D-alanine and ATP to ADP (Fig. 4S).
These results are consistent with the mechanism of ordered binding and the binding assays
reported by Prosser and de Carvalho with the polyhistidine tagged enzyme.8 The
experiments reported by Bruning et al. with the same untagged Ddl enzyme used in our
study, may have revealed a different Ddl conformation than the one assessed by our NMR
studies.
1D 1H-NMR line-broadening binding assays were also carried out with DCS, DCS and
ATP, and DCS with both ATP and D-alanine. The DCS NMR peaks broaden and incurred a
chemical shift change in all three cases indicating that, in contrast to D-alanine, DCS can
bind Ddl independently of ATP. Nonetheless, DCS is a weak binding ligand as evident by
the modest changes in line-width and chemical shifts consistent with reported Ki values of
14 μM8 to 0.9 mM.49
To confirm these results, we followed the progression of the Ddl (25 μM) reaction at
varying DCS concentrations and fixed amounts of D-alanine (100 μM) and ATP (100 μM).
Using NMR, the concentrations of the substrates (ATP and D-alanine) and two of the
products (ADP and D-alanyl- D-alanine) were determined over time (Fig. 4S). In the
absence of DCS, the conversion of ATP and D-alanine into ADP and D-alanyl-D-alanine
was stoichiometric, but followed a very slow kinetics, reaching a maximum conversion in
the forward reaction at approximately 4 h (Fig. 6a). Thereafter, the reaction was inhibited by
accumulation of the ADP and D-alanyl-D-alanine products. To analyze the inhibitory effect
of DCS, the reaction conditions were modified by adding saturating amounts of ATP at 6.0
mM. Under these conditions, the reaction proceeds to completion until D-alanine is
exhausted (Fig. 6b). At increasing DCS concentrations, the reaction is progressively
inhibited, but never reaches full inhibition. This is as expected given that DCS binds weakly
to Ddl and D-alanine is a competitor of DCS.
DISCUSSION
DCS is known to inhibit peptidoglycan biosynthesis, but its primary target has been a point
of controversy and extensive investigation for over fifty years. The effect of DCS has been
attributed to the inhibition of Alr, Ddl or both.32, 33, 43, 50 Both Alr and Ddl are known
binding targets in mycobacteria and their enzymatic activities are inhibited by DCS in a
concentration dependent manner.19, 35 Alr is the only known enzyme to produce D-alanine
in M. smegmatis and M. tuberuculosis. In addition, previous studies have shown that the
overexpression of alr confers resistance to DCS while alr mutant strains are more
susceptible.19, 33 However, overexpression of ddl also leads to DCS resistance, but to lower
levels.35 Similarly, contradictory genetic studies have been presented that seem to indicate
that Alr is required in the absence of D-alanine.43, 50 Nonetheless, as we have previously
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observed,19 these seemingly contradictory results may occur because of the different
experimental conditions employed by these various studies to analyze Alr conditional
essentiality. Critically, alr mutants are still able to grow in the absence of D-alanine. 32, 33
Also, the NMR metabolomic profiles of alr mutants do not match the metabolome of wild
type M. smegmatis treated with DCS, which indicates that Alr is not the main inhibitory
target of DCS.9 Thus, these studies taken together conclusively rule out Alr as the lethal
target of DCS in mycobacteria.
In this study, we found that DCS does not only inhibit peptidoglycan synthesis, but it also
caused a cascade of effects on the central metabolism of the cell (Fig. 7). Our NMR
metabolomics results using both 13C-glucose and 13C-pyruvate as carbon-13 sources
showed a large increase in the accumulation of peptidoglycan precursors, as would be
expected from DCS inhibition of peptidoglycan biosynthesis. Furthermore, DCS treatment
of both M. smegmatis and M. tuberculosis resulted in a metabolic shift towards a catabolic
state. We hypothesize that this catabolic shift occurs to compensate for the need to increase
the synthesis of peptidoglycan precursors used to construct the cell wall. The shift towards
the non-oxidative branch of the pentose phosphate pathway was evidenced by a decrease in
oxidative branch metabolites with a concomitant increase in ribose-5-phosphate. This effect
is most likely associated with the inhibition of peptidoglycan synthesis as ribose-5-
phosphate is used in the synthesis of UTP needed to generate UDP-N-acetyl-glucosamine,
which is the initial precursor in this biosynthetic step. This metabolic shift is also likely to
result in a decrease in mycolic acid formation since the pentose phosphate oxidative branch
is a major source of NADPH, which is required for the synthesis of mycolic and fatty acids.
This would be expected to further weaken the cell wall and contribute to the bactericidal
action of DCS.
The demonstration that a decrease in the biosynthesis of D-alanyl-D-alanine occurs
simultaneously with cell growth inhibition shows that Ddl is the primary target of DCS.
However, inhibition of Alr may contribute indirectly to the effect of DCS by simply
lowering the pools of D-alanine produced.32 The lower levels of D-alanine upon Alr
inactivation may allow DCS to outcompete D-alanine for Ddl binding. However the
inactivation of Alr would not prevent the cells from obtaining D-alanine from an alternative
pathway by transamination from pyruvate with concomitant production of glutamate as we
report here and elsewhere.9, 32, 33 Other investigators proposed that Alr, rather than Ddl, is
the main target of DCS based on the reversal of growth inhibition by externally added D-
alanine and the weak reversal activity of D-alanyl-D-alanine. 50 However, our results clearly
show that D-alanine and DCS are both competitors for Ddl binding, where a significant
increase in D-alanine concentration can mitigate DCS activity by the intracellular protection
of Ddl. Ddl is simply a kinetically inefficient enzyme and, correspondingly, a bottle neck in
peptidoglycan biosynthesis. The externally added D-alanine is simply increasing Ddl
activity by outcompeting DCS. Thus, increasing the intracellular pool of D-alanine is an
effective mechanism of increasing DCS resistance. Thus, our combined analysis in this and
previous studies indicate that DCS acts primarily on Ddl, an alternative pathway provides a
source of D-alanine when Alr activity is inhibited or deleted, and Alr plays an indirect role
in protecting Ddl by maintaining a higher internal pool of D-alanine. Importantly, these
insights will help guide future drug discovery efforts.
DCS is commonly used as a second-line treatment of drug-resistant TB despite its serious
side effects. These side effects are attributed to off-target activity and are consistent with our
NMR metabolomics study where DCS inhibits multiple targets in vivo. Correspondingly, our
identification that D-alanine-D-alanine ligase is the lethal target of DCS will support the
future design of DCS-derived drugs with reduced side effects. Simply, drug discovery
efforts can be focused on developing next-generation TB drugs by designing compounds
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that selectively inhibit D-alanine-D-alanine ligase. Furthermore, our detailed analysis of
changes in the metabolome due to DCS treatment will also be invaluable for validating the
desired in vivo activity of next-generation Ddl inhibitors. Selective inhibitors of Ddl should
induce metabolome perturbations comparable to DCS. Finally, our metabolomics study
identified that the over-production of D-alanine is a simple and effective mechanism of
resistance against Ddl inhibitors. Thus, a combination therapy for a DCS-derived drug may
be a more effective TB therapy; a Ddl inhibitor should be supplemented with inhibitors of
Alr and the predicted transaminase to prevent resistance. In conclusion, our detailed
metabolomics study resolved a 50-year old mystery regarding the in vivo lethal target of
DCS and laid the foundation for developing new TB therapies based on DCS and Ddl.
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Figure 1.
a) 1D 1H NMR spectra comparing the metabolome of M. tuberculosis and M. smegmatis
with (top) and without (bottom) treatment with DCS. The highlighted regions show the
major differences between the extracted metabolomes when treated with DCS. b) The
1D 1H NMR spectra of M. tuberculosis with (top) and without (bottom) treatment with DCS.
Key metabolite changes are labeled. Overlay of 2D 1H-13C HSQC spectra comparing
metabolite extracts from c) M. tuberculosis (black) and M. tuberculosis treated with 50 μg/
mL DCS (red), d) M. smegmatis (black) and M. smegmatis treated with 75 μg/mL DCS
(red). The circled region highlights the major differences between the untreated and treated
cultures. e) Highlighted region of the 2D 1H-13C HSQC spectra comparing M. tuberculosis
(red) and M. smegmatis (blue) treated with DCS, with a reference spectrum of D-alanyl-D-
alanine (black).
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Figure 2.
Bar graphs generated from the average of triplicate 2D 1H-13C HSQC spectra comparing the
differences between untreated (black) and DCS treated (white) M. smegmatis cultures using
a) 22 mM 13C-glucose or b) 100 μM 13C-pyruvate as the sole carbon-13 source. Metabolites
having statistically significant perturbations (p < 0.05) upon treatment with DCS are
displayed in the bar graph.
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Figure 3.
a) Heat map generated from the average of triplicate HSQC0 spectra comparing the relative
difference in metabolite concentrations between M. smegmatis and M. smegmatis treated
with 75, 300, or 1200 μg/mL DCS using 100 μM 13C-D-alanine as the carbon-13 source.
The relative differences between the untreated and treated cultures are plotted on a color
scale from −100% to −25% (red), −25% to 25% (black), and 25% to 1,200% (green). b) M.
smegmatis growth curve comparing untreated (black) cultures to cultures treated with 75
(magenta), 300 (blue), 1200 μg/mL (red) DCS. O.D values were determined after the
treatment of DCS with an initial O.D.600 of ~0.6.
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Figure 4.
Bar graphs depicting relative concentration differences in metabolite precursors a) alanine,
b) D-alanyl-D-alanine, c) glutamate, d) UDP, and e) lysine that are involved in the
biosynthesis of peptidoglycan. Error bars correspond to standard deviations in the relative
concentration differences. The observed metabolite concentration changes result from
treating M. smegmatis and M. smegmatis with DCS. A positive value indicates an increase in
the concentration of the metabolites when the cultures are treated with DCS, and a negative
value indicates a decrease in the concentration of the metabolites when the cultures are
treated with DCS.
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Figure 5.
Schematic representation of pathways that may synthesize D-alanine. Alr (red path) is
inhibited at a dose of 75 μg/mL of DCS, which inhibits the primary pathway of D-alanine
production. However, inhibiting Alr is non-lethal as a transaminase pathway (green path) is
hypothesized to remain unaffected upon DCS treatment. This reaction may lead to an
alternative mechanism of D-alanine biosynthesis that antagonizes DCS activity through a
competition for Ddl. Ddl (pink path) is inhibited at a dose of 1200 μg/mL of DCS, inhibition
of peptidoglycan biosynthesis initiates a cascade of events leading to cell death.52 TCA,
tricarboxylic acid.
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Figure 6.
NMR kinetic analysis of a) ADP and b) D-alanyl-D-alanine formation by Ddl. The 1D 1H
spectrum were collected at one hour intervals after the addition of 25 μM of Ddl into a
mixture containing 100 μM D-alanine and 100 μM ATP. c) Plot of D-alanyl-D-alanine
formation as monitored by 1D 1H NMR that demonstrates a decrease in Ddl activity as a
function of increasing DCS concentration: 0 (black), 250 (red), 500 (blue), 1000 (green) μM
of DCS.
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Figure 7.
Peptidoglycan biosynthesis pathway depicting the metabolites that were identified by
2D 1H-13C HSQC analysis or from literature results.53, 54 The arrows correspond to
metabolites with statistically significant (p < 0.05) concentration increases (up) or decreases
(down) when comparing DCS treated cells to untreated cells. Circles indicate the metabolite
concentration is similar (p > 0.05). The p values were calculated using the Student’s t-test.
Hyphens indicate the metabolites were not identified for the specific carbon-13 source. Cells
were incubated with 13C-glucose and treated with 75 μg/mL of DCS (black arrow), 13C-
pyruvate and treated with 75 μg/mL of DCS (red arrow), 13C-alanine and treated with 75 μg/
mL of DCS (grey arrow), 13C-alanine and treated with 300 μg/mL of DCS (blue
arrow), 13C-alanine and treated with 1200 μg/mL of DCS (dark blue arrow), and literature
data (pink arrows)
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Figure 1S: Ligand binding assays comparing the intensities of the ATP peaks (8.28 and 8.54ppm) in mixtures consisting of: a) 100 
μM ATP, D-alanine, DCS and 25 μM Ddl; b) 100 μM ATP and D-alanine and 25 μM Ddl; c) 100 μM ATP and 25 μM Ddl; and d) 
100 μM ATP as a control. 
 
  
Figure 2S: Ligand binding assays comparing the intensities of the D-alanine peaks (1.45-1.50) in mixtures consisting of: a) 100 μM 
ATP, D-alanine, DCS and 25 μM Ddl; b) 100 μM ATP and D-alanine and 25 μM Ddl; c) 100 μM D-alanine and 25 μM Ddl; and d) 
100 μM D-alanine as a control.  Formation of D-alanyl-D-alanine (1.33-1.38ppm) is formed when ATP, D-alanine, and Ddl are in the 
same mixture. 
 
  
Figure 3S: Ligand binding assays comparing the intensities of the DCS peaks (3.95-4.10 ppm) in mixtures consisting of: a) 100 μM 
ATP, D-alanine, DCS and 25 μM Ddl; b) 100 μM ATP, DCS and 25 μM Ddl; c) 100 μM DCS and 25 μM Ddl; and d) 100 μM DCS 
as a control.  
  
 
Figure 4S: 1D 
1
H NMR was used to monitor the conversion of (a) ATP (blue) to ADP (red) and (b) D-alanine (red) to D-alanyl-D-
alanine (blue) by Ddl. The initial concentrations were fixed at Ddl (25 μM)  D-alanine (100 μM) and ATP (100 μM).   
 
